Nuclear Medicine/Radiopharmaceuticals Market is is projected to expand at a healthy CAGR of 5.9% by 2023
The nuclear medicine market is projected to reach USD 5.26 billion by 2023 from an estimated USD 3.95 billion in 2018, at a CAGR of 5.9%. Growth in this market is mainly driven by factors such as the increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99. Moreover, the use of radiopharmaceuticals in novel neurological applications...
Nuclear Medicine / Radiopharmaceutical Market expected to reach $5.55 Billion by 2017 at CAGR of 7.8%
The “Healthcare” practice at MarketsandMarkets is pleased to announce its “Analyst Briefing Presentation” on the “Nuclear Medicine/Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) Market – Global Trends & Forecast to 2017”
The...